Development of an MHC class I Ld-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 2, 2011, Pages 118-121

  Lemke, C D ^a   Graham, J B ^b   Lubaroff, D M ^c   Salem, A K ^a  

^a UNIVERSITY OF IOWA   (United States)

^b University of Iowa   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

intracellular cytokine staining; MHC tetramer; mouse; PSA

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CD8 ANTIGEN; GAMMA INTERFERON; HISTIDYLPROLYLGLUTAMINYLLYSYLVALYLTHREONYLLYSYLPHENYLALANYLMETHIONYLLEUCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; PROSTATE SPECIFIC ANTIGEN; TETRAMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE ACTIVATION;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; MODELS, IMMUNOLOGICAL; PEPTIDE FRAGMENTS; PROSTATE-SPECIFIC ANTIGEN; PROTEIN STRUCTURE, QUATERNARY; STAINING AND LABELING;

EID: 79956140723     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.57     Document Type: Article

References (25)

1. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992; 58: 143-175
2. Engleman EG, Brody J, Soares L. Using signaling pathways to overcome immune tolerance to tumors. Sci STKE 2004; 2004: pe28
3. Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 2004; 113: 774-783 (Pubitemid 38544171)
4. Morris E, Hart D, Gao L, Tsallios A, Xue SA, Stauss H. Generation of tumor-specific T-cell therapies. Blood Rev 2006; 20: 61-69
5. Blohm U, Potthoff D, van der Kogel AJ, Pircher H. Solid tumors 'melt' from the inside after successful CD8 T cell attack. Eur J Immunol 2006; 36: 468-477 (Pubitemid 43257470)
6. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 2007; 204: 345-356 (Pubitemid 46294550)
7. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308 (Pubitemid 351430867)
8. Saha A, Bhattacharya-Chatterjee M, Foon KA, Celis E, Chatterjee SK. Stimulatory effects of CpG oligodeoxynucleotide on dendritic cellbased immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice. Int J Cancer 2009; 124: 877-888
9. Davila E, Celis E. Repeated administration of cytosinephosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000; 165: 539-547 (Pubitemid 30429549)
10. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90: 1894-1900 (Pubitemid 29014223)
11. Siemens DR, Elzey BD, Lubaroff DM, Bohlken C, Jensen RJ, Swanson AK et al. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol 2001; 166: 731-735 (Pubitemid 32060221)
12. Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer 2001; 94: 842-849 (Pubitemid 33032833)
13. Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 2002; 62: 5260-5266 (Pubitemid 35024600)
14. Lubaroff DM, Karan D, Andrews MP, Acosta A, Abouassaly C, Sharma M et al. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine 2006; 24: 6155-6162 (Pubitemid 44202567)
15. Karan D, Krieg AM, Lubaroff DM. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer 2007; 121: 1520-1528 (Pubitemid 47328711)
16. Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Eur J Immunol 2009; 39: 2725-2736
17. Lubaroff DM, Karan D. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. Adv Drug Deliv Rev 2009; 61: 268-274
18. Drake CG. Immunotherapy for prostate cancer: an emerging treatment modality. Urol Clin North Am 2010; 37: 121-129, Table of Contents
19. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer- Williams MG, Bell JI et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-96 (Pubitemid 26332731)
20. Turner MJ, Abdul-Alim CS, Willis RA, Fisher TL, Lord EM, Frelinger JG. T-cell antigen discovery (T-CAD) assay: a novel technique for identifying Tcell epitopes. J Immunol Methods 2001; 256: 107-119 (Pubitemid 32769921)
21. Marshall DJ, San Mateo LR, Rudnick KA, McCarthy SG, Harris MC, McCauley C et al. Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine. Cancer Immunol Immunother 2005; 54: 1082-1094 (Pubitemid 41396813)
22. Rammensee HG. Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 1995; 7: 85-96
23. Demant P, Ivanyi D, Oudshoorn-Snoek M, Calafat J, Roos MH. Molecular heterogeneity of H-2 antigens. Immunol Rev 1981; 60: 5-22 (Pubitemid 12220946)
24. Altman JD, Davis MM. MHC-peptide tetramers to visualize antigen-specific T cells. Curr Protoc Immunol 2003 Chapter 17: Unit 17.13
25. Kim JJ, Yang JS, Dang K, Manson KH, Weiner DB. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin Cancer Res 2001; 7: 882s-889s (Pubitemid 33600941)